Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14
April 29 2020 - 2:47PM
Business Wire
Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van
Bokkelen, Chairman and CEO, will present a corporate overview at
the Bank of America Merrill Lynch 2020 Virtual Healthcare
Conference to investors and analysts. The presentation is scheduled
for Thursday, May 14, 2020 at 8:20 a.m. EDT.
Dr. Van Bokkelen will provide a brief overview of the Company’s
mission and its therapeutic platform, MultiStem® cell therapy. The
presentation will include information on the critical care
indications in the Company’s progressing clinical pipeline,
including the Phase 2/3 pivotal trial evaluating MultiStem cell
therapy for the treatment of COVID-19 induced acute respiratory
distress syndrome (ARDS) and its ongoing Phase 3 trial of MultiStem
cell therapy for the treatment of ischemic stroke. The Company will
also engage in virtual meetings with other institutional
representatives at the conference.
A live webcast of the presentation can be accessed at the
following link:
http://www.veracast.com/webcasts/bofa/healthcare2020/id85592049.cfm
or by visiting ‘Events & Presentations’ in the Investors
Section on the Company's website. An archived replay of the webcast
will be available one hour after the conclusion of the live event
on the Company's website after the conference for a limited
time.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
"off-the-shelf" stem cell product, initially for disease
indications in the neurological, inflammatory and immune,
cardiovascular and other critical care indications and has several
ongoing clinical trials evaluating this potential regenerative
medicine product. Athersys has forged strategic partnerships and a
broad network of collaborations to further advance the MultiStem
cell therapy toward commercialization. More information is
available at www.athersys.com. Follow
Athersys on Twitter at www.twitter.com/athersys.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200429005806/en/
Ivor Macleod Chief Financial Officer Tel: (216) 431-9900
ir@athersys.com
Karen Hunady Director of Corporate Communications & Investor
Relations Tel: (216) 431-9900 khunady@athersys.com
David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858)
717-2310 David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024